Subash Chandra Mohanta

Title: Innovations by Subash Chandra Mohanta

Introduction

Subash Chandra Mohanta is a notable inventor based in Noida, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of delayed release formulations. With a total of two patents to his name, his work showcases innovative approaches to drug delivery systems.

Latest Patents

Subash Chandra Mohanta's latest patents include a "Delayed release pharmaceutical composition of pantoprazole and process for formulation thereof." This invention discloses a stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds. The formulation comprises a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients. It also features a water-soluble seal coating over the core and an enteric coating layer, ensuring that the core is free of surfactants. The prior art has disclosed restrictive formulation techniques, suggesting higher amounts of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes such as drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and compatibility with packaging material.

Career Highlights

Subash Chandra Mohanta is currently associated with Jubilant Generics Limited, where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to improving drug formulations and enhancing patient outcomes.

Collaborations

Some of his notable coworkers include Kamal Surendrakumar Mehta and Saurabh Srivastava, who contribute to the collaborative environment at Jubilant Generics Limited.

Conclusion

Subash Chandra Mohanta's contributions to pharmaceutical innovations, particularly in delayed release formulations, highlight his expertise and commitment to advancing drug delivery systems. His patents reflect a significant step forward in the field, benefiting both the industry and patients alike.